@entity1421 ( @entity1421 ) is a key mediator of exaggerated @entity158 sensation during @entity32 . Drugs targeting the @entity1421 pathway by global inhibition of cyclooxygenases are well established in the treatment of @entity158 , but also cause significant unwanted effects. Enzymes downstream of the cyclooxygenases, or @entity3009 receptors are candidate targets possibly enabling therapeutic intervention with potentially fewer side effects. Among the PGE(2) receptors, the @entity17782 subtype has repeatedly been proposed as a promising target for treatment of @entity1931 . However its involvement in sensitization at specific (peripheral or central) sites has not been thoroughly investigated. Here, we have used @entity19 deficient in the @entity17782 receptor ( @entity17782 (-/-)) to address this issue. @entity17782 (-/-) @entity19 showed normal mechanical and heat sensitivity during baseline conditions. Local subcutaneous @entity1421 injection into one hindpaw, caused thermal and mechanical sensitization in wild-type @entity19 and @entity17782 (-/-) @entity19 . Thermal sensitization in @entity17782 (-/-) @entity19 was less than in wild-type @entity19 while no significant difference was seen for mechanical sensitization. Injection of @entity1421 into the subarachnoid space of the lumbar spinal cord, resulted in a similar mechanical sensitization in @entity17782 (-/-) @entity19 and in wild-type @entity19 , while a tendency towards reduced reaction to noxious heat stimulation was observed in @entity17782 (-/-) @entity19 . These results support a major contribution of @entity17782 receptors to peripheral heat sensitization, but only a minor role in mechanical sensitization and in spinal heat sensitization by @entity1421 . After local subcutaneous zymosan A injection, @entity17782 (-/-) @entity19 showed indistinguishable mechanical and heat sensitization compared with wild-type @entity19 . Taken together, these results suggest that peripheral @entity17782 receptors contribute significantly to @entity32 induced @entity158 sensitization while evidence for a contribution to central sensitization was not obtained.

Contribution of peripheral versus central XXXX prostaglandin receptors to @entity158 .

@entity17782 :: ('19216(Tax:10090)', 'Gene') :: ['EP1'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity1931 :: ('MESH:D006930', 'Disease') :: ['inflammatory hyperalgesia'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity1421 :: ('MESH:D015232', 'Chemical') :: ['PGE(2)', 'Prostaglandin E(2)'] @entity3009 :: ('CHEBI:26333', 'Chemical') :: ['prostaglandin'] @entity158 :: ('MESH:D010146', 'Disease') :: ['inflammatory pain', 'pain', 'heat pain']
@entity17782 :: (19216(Tax:10090),Gene) :: ['EP1']
